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It was indeed a
party to celebrate
the results of the
PARTNER trial.
An almost halving
of mortality is not
to be sneezed at,
and is unheard of
in interventional
cardiology trials
famous for utiliz-
ing component sur-
rogate end points to
achieve statistical
power.
Are more trials
needed, or would
further randomiza-
tion just be tribula-
tion for the physi-
cians and patients
with no options save
hospice and valve
implantation?DITOR’S PAGE
rials, Triumphs, and Tribulations
he ballroom in our nation’s capitol was packed with thousands expectantly awaiting the
resentation of the results. Never has a march on Washington energized so many . . . (inter-
entional cardiologists). Was it a political party, a tea party, or just a party? It was indeed a
arty to celebrate the results of the PARTNER trial. There were no gasps of disbelief or
hocked expressions of surprise, but a quiet recognition that a new era in medicine was
awning. A positive trial was anticipated, and the magnitude of the win did not disappoint.
The Transcatheter Cardiovascular Therapeutics (TCT) meeting has become famous for big
roduction numbers, but the lead-in to this late-breaking trial would have put Broadway to
hame. A parade of surgeons and cardiologists who have distinguished themselves as “gurus” of
alvular heart disease talked of the challenge of end-stage aortic stenosis using all currently
vailable therapies. A patient just short of her 100th birthday testified to the vigorous new life
he had gained from the valve of a stallion, which had saved both her life and the quality of
er life. (I thought it was a bovine valve but she was just happy it was not from a pig.) I must
dmit that she looked so good that in another era she could have sold a lot of “Dr. Smith’s
iracle Youth Elixir.” Finally, with the IMAX and surround sound environment of the
ashington Convention Center ballroom in full display, Dr. Marty Leon reported for the
nvestigators the results of the PARTNER trial group B. It was a monumental undertaking,
nd the investigators deserve enormous credit for the quality of the study.
As we know by now, these were the sickest of the sick. They were aortic stenosis patients,
verage age 83 years, who were turned down for surgery by some of the country’s best
urgeons. It is hard to find a group of patients with any disease who have a 50% 1-year
ortality, but this was the fate of the patients who were randomized to medical therapy only.
hat therapy pulled out all the stops, including aortic valvuloplasty performed in 83% of the
ontrol group, but still one-half died by 1 year. Insertion of percutaneous aortic valves, on the
ther hand, resulted in 70% of patients alive and mostly well at 1 year. There is no question
hat those who made the pilgrimage to Washington were rewarded with the knowledge that
hey could tell their grandchildren they were there when it was established that there is no
uch thing as an untreatable patient with terminal aortic stenosis.
But why was surprise missing? Were there leaks of the data? Surely we now know the
enalty for that! No, the results of the trial were tightly held even from the investigators. Yet,
hy was no one shocked? There was only one reason that this trial would not have been
ositive. The valve would be a dud! The valve, as futuristic as it may have seemed 2 to 3 years
go, is not viewed as a pipe dream but as a reality. Our European colleagues, unaccustomed to
ood and Drug Administration (FDA) regulations, have implanted over 20,000 aortic valves
ith results that convinced them that the valves were not duds. So, will the impact of the trial
ive up to the accolades given to it by my colleague, Peter Block (one of the authors of the
eport) who told me on a CVN interview, “This is the best interventional cardiology trial in a
ecade.” Is it? Let’s have a look. Certainly this is a very positive trial. An almost halving of
ortality is not to be sneezed at, and is unheard of in interventional cardiology trials famous
or utilizing component surrogate end points to achieve statistical power. But is the trial the
hing we should celebrate? Alain Cribier and his mentor Bruce Letac started us on the path to
eal with aortic stenosis using balloon angioplasty. The failure of that technique did not
issuade Cribier, and his role in the development of transcatheter aortic-valve implantation was
ppropriately celebrated with the lifetime achievement award at TCT. The valves currently
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1207vailable for investigation and therapy exceed most of our
xpectations, and we hope that excitement will extend
eyond the short follow-up we have at present, but 5 to
0 years from now we may view these devices as
rimitive.
Whether the use of these valves in a broader group of
atients will be competitive with surgical repair will be
ested in the PARTNER group A study, and this was not
stablished at the time of writing this page. However,
heir use in the no-option patients studied in PARTNER
roup B poses some interesting regulatory and ethical
ssues. Are more trials needed, or would further
andomization just be tribulation for the physicians and
atients with no options save hospice and valve
mplantation? Incremental improvements in valves will
ppropriately require FDA oversight, but will that prevent
he use of such devices in patients with no other option?
ram Zuckerman of the FDA, after praising the trial and
he investigators, pointed out that the responsibility of the
DA is to analyze the trial and other evidence. He sointed to the variably controlled use outside the U.S.,
he short-term follow-up, and the complex engineering
equired to consistently provide a safe and durable
roduct as reasons that careful evaluation is needed.
angerous or futile therapies have no place in medical
ractice even for desperate and end-stage situations, but is
he current evidence adequate for the use of these devices
n appropriately risk-stratified patients who have no other
ption? The PARTNER group B trial may live up to its
pectacular debut as a game changer for the sickest of the
ick. For others, we will have to wait on further evidence,
ncluding group A results.
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